netFormulary Oxfordshire Clinical Commissioning Group NHS
Formulary  
 Search
 Formulary Chapter 6: Endocrine system - Full Chapter
06.01.02.03  Expand sub section  Other antidiabetic drugs
06.01.02.03  Expand sub section  Alpha glucosidase inhibitors
06.01.02.03  Expand sub section  DPP4 inhibitors (gliptins)
06.01.02.03  Expand sub section  GLP1 agonists
Liraglutide 1.2mg (Victoza®)
View adult BNF View SPC online View childrens BNF
Restricted Drug Restricted
Brown

First line option in line with updated GLP-1 receptor agonist guidelines.

See patient agreement form.

APCO September 2019.

 
Link  NICE TA203: Diabetes (type 2) - liraglutide
   
Liraglutide 1.8mg (Victoza®)
View adult BNF View SPC online View childrens BNF
Restricted Drug Restricted
Brown

GP can titrate to 1.8mg if partial response. If no response consider one of the more cost effective options

See GLP-1 receptor agonist guidelines and patient agreement form.

APCO September 2019.

 
   
Dulaglutide (Trulicity®)
View adult BNF View SPC online View childrens BNF
Restricted Drug Restricted
Brown

First line option in line with updated GLP-1 receptor agonist guidelines (previously for those who would gain benefit from once weekly and can’t have semaglutide).

See patient agreement form.

APCO September 2019.

 
Link  NICE Evidence Summary: Dulaglutide for Type 2 diabetes
   
Exenatide (Byetta▼®)
View adult BNF View SPC online View childrens BNF
Restricted Drug Restricted
Brown

Existing patients only (unless high CV risk) in line with updated GLP-1 receptor agonist guidelines

See patient agreement form.

APCO September 2019.

 
Link  MRHA: Risk of severe pancreatitis and renal failure with Exenatide
   
Exenatide prolonged release (Bydureon▼®)
View adult BNF View SPC online View childrens BNF
Restricted Drug Restricted
Brown

Restricted to existing patients only.

Prescribe semaglutide as first line prolonged release glucagon–like peptide (GLP-1) receptor agonist treatment in line with GLP-1 receptor agonist guidelines. Existing patients who meet NICE criteria for continuation can continue with treatment.

Not included in the GLP-1 receptor agonist guidelines. See patient agreement form.

APCO September 2019.

 
Link  MHRA: Risk of severe pancreatitis and renal failure with Exenatide
Link  NICE TA248: MR exenatide
   
Lixisenatide (Lyxumia▼®)
View adult BNF View SPC online View childrens BNF
Restricted Drug Restricted
Brown

Restricted Item 

Existing patients only (unless high CV risk) in line with updated GLP1 guidelines.

See patient agreement form.

APCO September 2019.

 
   
Semaglutide (Ozempic®)
View adult BNF View SPC online View childrens BNF
Restricted Drug Restricted
Brown

First line option in line with updated GLP1 guidelines (previously for those who would gain benefit from once weekly). If eye disease present, see flowchart. 

See patient agreement form.

APCO September 2019.

 

 
   
06.01.02.03  Expand sub section  Meglitinides to top
06.01.02.03  Expand sub section  SGL2 inhibitors
06.01.02.03  Expand sub section  Thiazolidinediones
 ....
Key
note Notes
Section Title Section Title (top level)
Section Title Section Title (sub level)
First Choice Item First Choice item
Non Formulary Item Non Formulary section
Restricted Drug
Restricted Drug
Unlicensed Drug
Unlicensed
Track Changes
Display tracking information
click to search medicines.org.uk
Link to adult BNF
click to search medicines.org.uk
Link to children's BNF
click to search medicines.org.uk
Link to SPCs
SMC
Scottish Medicines Consortium
Cytotoxic Drug
Cytotoxic Drug
CD
Controlled Drug
High Cost Medicine
High Cost Medicine
Cancer Drugs Fund
Cancer Drugs Fund
NHSE
NHS England
Homecare
Homecare
CCG
CCG

Traffic Light Status Information

Status Description

Red

Red: Medicines which should only be prescribed in secondary care by a specialist.  

Amber Continuation

Amber Continuation: Medicines which should be initiated or recommended by a specialist for continuation in primary care. The specialist must notify the GP that the prescribing responsibility has been transferred.   

Amber Shared Care Protocol

Amber Shared Care Protocol: Medicines which are appropriate to be initiated and stabilised by a specialist, once stabilised the medicine may be appropriate for responsibility to be transferred from secondary to primary care with the agreement of a GP and a formal ‘shared care’ agreement. The shared care protocol must be approved by the Area Prescribing Committee Oxfordshire (APCO).   

Green

Green: Medicines which are suitable for initiation and ongoing prescribing within primary care.   

Brown

Brown: Medicines which should only be prescribed in restricted circumstances.  

Black

Black: Medicines which are not recommended for use because of lack of evidence of clinical effectiveness, cost effectiveness or safety.  

OCCG Green

not used  

netFormulary